PDI Moves into MDx Space with Acquisition of Two Asuragen microRNA Tests | GenomeWeb

NEW YORK (GenomeWeb) – PDI said after the close of the market Wednesday that its Interpace Diagnostics subsidiary will enter the molecular diagnostics market through the acquisition of two tests from Asuragen.

PDI said that it will pay Asuragen $8 million upfront in cash, future commercial milestone-based payments, and royalties for the miRInform Thyroid and Pancreas cancer tests, IP related to the tests and other tests in development for thyroid cancer, as well as a tissue sample biobank containing more than 5,000 samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.